Lexicon Pharmaceuticals (LXRX) reported a third-quarter loss of $0.03 per share, half the $0.06 loss consensus expected. That is a 50.0% earnings surprise, and the per-share loss narrowed 25.0% from a year ago. Revenue of $11.25 million topped the $10.9 million estimate by 3.2% but fell 20.7% year over year. The headline beat is real, but it says little about the business. The more important development is that the quarter produced genuine clinical de-risking while the regulatory timeline slipped again. That is the central tension heading into a catalyst-heavy early 2027.
The quality of the beat deserves scrutiny. The net loss actually widened to $14.0 million from $12.8 million, and the operating loss grew to $14.5 million from $12.2 million. The smaller per-share loss came largely from a much bigger denominator. Weighted average shares rose to roughly 445 million from 363 million after the February equity raise. Revenue is still dominated by partner payments. Total revenue consisted mostly of a $10.0 million Novo Nordisk milestone, while INPEFA sold just $1.2 million. That product line is growing only incrementally and remains immaterial. R&D fell to $16.2 million from $18.8 million as the PROGRESS trial costs rolled off, partly offset by SONATA-HCM spending. SG&A rose to $9.5 million from $7.6 million on pre-commercialization costs. Cash and investments stood at $183.2 million, still well funded. But the balance has drifted down from $199.7 million in the first quarter and $190.6 million in the second. Management reiterated 2026 operating expense guidance of $100-$110 million.
The operating story improved on substance. STENO1, the investigator-initiated study, met the FDA's agreed exposure requirements, with 496 sotagliflozin patients and 708 standard-of-care patients at the August cutoff. It showed roughly one diabetic ketoacidosis (DKA) event per 100 patient-years, comparable to standard of care. Management had previously cited an FDA bar of about 3.5 per 100 patient-years, so this rate sits well below it. That directly addresses the safety concern that sank ZYNQUISTA the first time. SONATA-HCM closed at 542 patients against a target of roughly 500, with a mean baseline KCCQ score of 59. Topline data remain on track for the first quarter of 2027. Novo paid its third $10 million LX9851 milestone, completing the $30 million in 2026 payments management had flagged. Lexicon has now collected $75 million of up to $1 billion under that deal. Pilavapadin also picked up a new preclinical obesity angle. It produced 14% weight loss alone and 31% combined with semaglutide, versus 25% for semaglutide alone.
Bears have legitimate ammunition, however. The ZYNQUISTA NDA resubmission has now slipped a third time. It moved from mid-2026, to end-October 2026, and now to the first quarter of 2027. The "approval in 2026" framing from earlier calls is gone. Management attributed the delay to reformatting investigator-generated STENO1 data to regulatory standards, with FDA alignment on analysis parameters still ongoing. That explanation is plausible, but repeated slippage erodes credibility on timelines. SONATA-HCM's mix is another issue. It is heavily weighted toward non-obstructive patients (440 of 542), leaving a small 102-patient obstructive cohort. The primary endpoint covers the entire population. SotaCross was pushed to 2027. The pilavapadin partnering narrative emphasized earlier in the year went unmentioned, with no deal announced.
The market had already priced in plenty of skepticism. Shares closed at $1.48 on the eve of the report, 24.5% below the $1.96 open after the August release. That leaves the stock about 21.4% under its $1.88 200-day moving average. It has also given back nearly all of its post-report spike to $2.49 on August 10, sitting 40.6% below that high. Shares are just 8.4% above the October 23 low of $1.37. Investor sentiment nonetheless improved, moving from mildly negative (-0.12) to roughly neutral (+0.03). The shift is modest and suggests expectations were stabilizing rather than turning enthusiastic. Trend readings are mixed: momentum has turned positive, while the price trend and AVWAP remain negative.
The practical effect is that Lexicon's investment case has compressed into a narrow window. Both SONATA-HCM topline data and the ZYNQUISTA resubmission are now slated for the first quarter of 2027. That concentrates binary risk, but it also gives investors a defined test of the cardiometabolic strategy. The cash balance appears sufficient to reach that point.
The bottom line is that Lexicon's EPS beat is mostly a share-count artifact on a modest revenue base, and it should not be read as operating progress. What did move forward was the evidence. STENO1's DKA data strengthen the ZYNQUISTA filing, and an overenrolled SONATA-HCM keeps the larger HCM opportunity intact. Against that, a third resubmission delay and a stock trading well below its trend lines show investors want execution, not promises, before re-rating the shares.